KINARUS THERAPEUTICS HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0034 CHF | 0.00% |
|
-10.53% | +750.00% |
| Mar. 28 | Swiss Exchange Regulator Drops Inquiry Into Kinarus Therapeutics | MT |
| Feb. 06 | Kinarus Therapeutics Receives Swiss Court Approval for Revocation of Bankruptcy | MT |
More news
More press releases
More news
| 1 week | -10.53% | ||
| Current month | -26.09% | ||
| 1 month | -22.73% | ||
| 3 months | +325.00% | ||
| 6 months | +325.00% | ||
| Current year | +750.00% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.01
1 year
0.000.01
3 years
0.000.05
5 years
0.000.05
10 years
0.000.05
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Bausch
CEO | Chief Executive Officer | - | - |
Claudia Berger
CTO | Chief Tech/Sci/R&D Officer | - | - |
Matthew Wright
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexander Bausch
CEO | Chief Executive Officer | - | - |
Hari Kumar
CHM | Chairman | 69 | - |
| Director/Board Member | 59 | - |
Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
Sector
Airlines
Calendar
2024-06-20
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +750.00% | 3.99M | |
| -26.82% | 1.85B | |
| +33.40% | 296M | |
| -14.55% | 81.24M | |
| -46.22% | 65.82M |
- Stock Market
- Equities
- KNRS Stock
